ClinicalTrials.gg
CompletedNCT05291689EMERALD-1Updated Mar 11, 2026Results posted

A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

A Phase 2 interventional study of MORF-057 in Inflammatory Bowel Diseases and Colitis, Ulcerative, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Primary conditionColitis, UlcerativeRegistry: Inflammatory Bowel DiseasesReclassifiedWhy we changed it
Registry
Inflammatory Bowel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colitis, Ulcerative
Why
  1. The study's listed conditions name Colitis, Ulcerative, a narrower term within Inflammatory Bowel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Colitis, Ulcerative by Eli Lilly and Company — 5 open to participants now, 7 under way, 3 of them phase 3. Colitis, Ulcerative · Eli Lilly and Company.

Enrollment
14th of 16
39 · median 211
Started
2022
with 1 other
Phase 2
8 of 16
3 open now
Registered
8th of 16
by date

Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 2, and was the 8th registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 16 studies in Colitis, Ulcerative by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Colitis, Ulcerative by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)

Read the detailed description

The main part of this Phase 2a study will consist of 3 study periods: a Screening Period, a Treatment Period and a Safety Follow-up Period. All participants who complete the open-label Treatment Period will have the opportunity to continue their treatment in an optional 26-week Long-term Extension study after completing the Week 52 assessments.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Colitis, Ulcerative

Browse trials for

Keywords

  • Ulcerative Colitis (UC)
  • Inflammatory Bowel Disease (IBD)
  • a4b7
  • Moderately to severely active ulcerative colitis
  • Integrin
04

In context

Colitis, Ulcerative Reclassified

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

This study's enrollment of 39 is below the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.

Browse Colitis, Ulcerative studies →

Lead sponsor

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company.

Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has signs/symptoms of moderately to severely active UC for at least 3 months prior to Screening
  • Has evidence of UC extending at least 15 cm from the anal verge
  • Is bio-naïve or had an inadequate response, loss of response, or intolerance to other UC drugs
  • Agrees to abide by the study guidelines and requirements
  • Capable of giving signed

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn's disease
  • Has positive findings on a subjective neurological screening questionnaire
  • Has a concurrent, , serious, unstable comorbidity
  • Primary non-responder to vedolizumab or other integrin inhibitors
  • Participation in any other interventional study or received any therapy within 30 days
  • Previous exposure to MORF-057 and/or a known to drugs with a similar mechanism to MORF-057
  • Unable to attend study visits or comply with study procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    MORF-057

    Participants received MORF-057 100 milligrams (mg) orally twice daily for up to 78 weeks.

    Drug: MORF-057

Interventions

  • MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

    Also known as: LY4268989

07

What researchers measure

Primary outcomes

  1. Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score

    Robarts Histopathology Index (RHI) Score: the total RHI Score ranges from 0 (no disease activity) to 33 (severe disease activity)

    Time frame: From baseline to 12 weeks

Secondary outcomes

  1. Main Cohort: Change From Baseline to Week 12 in the Modified Mayo Clinic Score

    The Modified Mayo Clinic Score (mMCS) is a composite of the following Mayo Clinic Score subscores: Endoscopy subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration), Stool Frequency subscore (range: 0=Normal number of stools for this participant to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The total mMCS ranges from 0 to 9, with higher scores indicating more severe disease.

    Time frame: From baseline to 12 weeks

  2. Main Cohort: Maximum Plasma Concentration (Cmax) During Multiple Doses of MORF-057

    To determine the Maximum Plasma Concentration of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.

    Time frame: 12 weeks

  3. Main Cohort: Time to Reach Cmax (Tmax) During Multiple Doses of MORF-057

    To determine the Tmax of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.

    Time frame: 12 weeks

  4. Main Cohort: Area Under the Curve (AUC) Following Multiple Doses of MORF-057

    To determine the area under the concentration-time curve of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.

    Time frame: 12 weeks

08

Results

Posted Nov 26, 2024

Participant flow

The study plan included two cohorts. Both cohorts receive the same MORF-057 treatment regimen. * Main cohort for formal assessment of study objectives. Participants in this cohort were biologic-naïve or previously exposed to biologic therapies, with no prior vedolizumab exposure. * Exploratory cohort for exploratory purposes only and not used to assess the study objectives. Participants in this cohort had prior vedolizumab exposure with intolerance or secondary non-response.

Participant flow — Overall Study
MilestoneMORF-057 (Main Cohort)MORF-057 (Exploratory Cohort)
Started354
Received at least one dose of study drug354
Completed171
Not completed183
Withdrew: Adverse event33
Withdrew: Lack of efficacy80
Withdrew: Withdrawal by subject70

Outcome measures

PrimaryMain Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score

Robarts Histopathology Index (RHI) Score: the total RHI Score ranges from 0 (no disease activity) to 33 (severe disease activity)

Time frame:
From baseline to 12 weeks
Reported as:
Mean · score on a scale
Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score
score on a scaleMORF-057 (Main Cohort)
Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score-6.4 ± 11.18
SecondaryMain Cohort: Change From Baseline to Week 12 in the Modified Mayo Clinic Score

The Modified Mayo Clinic Score (mMCS) is a composite of the following Mayo Clinic Score subscores: Endoscopy subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration), Stool Frequency subscore (range: 0=Normal number of stools for this participant to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The total mMCS ranges from 0 to 9, with higher scores indicating more severe disease.

Time frame:
From baseline to 12 weeks
Reported as:
Mean · score on a scale
Main Cohort: Change From Baseline to Week 12 in the Modified Mayo Clinic Score
score on a scaleMORF-057 (Main Cohort)
Main Cohort: Change From Baseline to Week 12 in the Modified Mayo Clinic Score-2.3 ± 2.14
SecondaryMain Cohort: Maximum Plasma Concentration (Cmax) During Multiple Doses of MORF-057

To determine the Maximum Plasma Concentration of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.

Time frame:
12 weeks
Reported as:
Geometric mean · ng/mL
Main Cohort: Maximum Plasma Concentration (Cmax) During Multiple Doses of MORF-057
ng/mLMORF-057 (Main Cohort)
Main Cohort: Maximum Plasma Concentration (Cmax) During Multiple Doses of MORF-057766 ± 46.4
SecondaryMain Cohort: Time to Reach Cmax (Tmax) During Multiple Doses of MORF-057

To determine the Tmax of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.

Time frame:
12 weeks
Reported as:
Geometric mean · hours
Main Cohort: Time to Reach Cmax (Tmax) During Multiple Doses of MORF-057
hoursMORF-057 (Main Cohort)
Main Cohort: Time to Reach Cmax (Tmax) During Multiple Doses of MORF-0572.014 ± 58.4534
SecondaryMain Cohort: Area Under the Curve (AUC) Following Multiple Doses of MORF-057

To determine the area under the concentration-time curve of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.

Time frame:
12 weeks
Reported as:
Geometric mean · hours*ng/mL
Main Cohort: Area Under the Curve (AUC) Following Multiple Doses of MORF-057
hours*ng/mLMORF-057 (Main Cohort)
Main Cohort: Area Under the Curve (AUC) Following Multiple Doses of MORF-0573070 ± 45.7

Adverse events

Collected over From baseline to week 78. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MORF-057 (Main Cohort)0/35 (0%)0/35 (0%)19/35 (54.3%)
MORF-057 (Exploratory Cohort)0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventMORF-057 (Main Cohort)MORF-057 (Exploratory Cohort)
Colitis ulcerativeGastrointestinal disorders7/354/4
AnaemiaBlood and lymphatic system disorders3/351/4
Fungal skin infectionInfections and infestations0/351/4
SinusitisInfections and infestations1/351/4
ErythemaSkin and subcutaneous tissue disorders0/351/4
HypertensionVascular disorders1/351/4
Anal fistulaGastrointestinal disorders2/350/4
Covid-19Infections and infestations2/350/4
NasopharyngitisInfections and infestations2/350/4
Upper respiratory tract infectionInfections and infestations2/350/4

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)MORF-057 (Main Cohort)MORF-057 (Exploratory Cohort)Total
Mean39.2 ± 14.159.5 ± 14.3641.3 ± 15.27
Age, Customized
Age, Customized(Participants)MORF-057 (Main Cohort)MORF-057 (Exploratory Cohort)Total
18 to 64 years34236
65 to 84 years123
Sex: Female, Male
Sex: Female, Male(Participants)MORF-057 (Main Cohort)MORF-057 (Exploratory Cohort)Total
Female16117
Male19322
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MORF-057 (Main Cohort)MORF-057 (Exploratory Cohort)Total
Hispanic or Latino101
Not Hispanic or Latino34438
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MORF-057 (Main Cohort)MORF-057 (Exploratory Cohort)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White35439
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)MORF-057 (Main Cohort)MORF-057 (Exploratory Cohort)Total
United States718
Poland28331
09

Study locations

17 sites
  • Clinical Study Site
    Tampa, Florida 33609, United States
  • Clinical Study Site
    Lafayette, Louisiana 70503, United States
  • Clinical Study Site
    Freehold, New Jersey 07728, United States
  • Clinical Study Site
    Brooklyn, New York 11235, United States
  • Clinical Study Site
    New York, New York 10075, United States
  • Clinical Study Site
    Bydgoszcz, 85-794, Poland
  • Clinical Study Site
    Elblag, 82-300, Poland
  • Clinical Study Site
    Katowice, 40-748, Poland
  • Clinical Study Site
    Lodz, 90-349, Poland
  • Clinical Study Site
    Lodz, 90-752, Poland
  • Clinical Study Site
    Oświęcim, 32-600, Poland
  • Clinical Study Site
    Sopot, 81-756, Poland
  • Clinical Study Site
    Sosnowiec, 41-209, Poland
  • Clinical Study Site
    Staszów, 28-200, Poland
  • Clinical Study Site
    Tychy, 43-100, Poland
  • Clinical Study Site
    Warsaw, 00-728, Poland
  • Clinical Study Site
    Warsaw, 02-665, Poland
10

References and documents

Publications

  • Sands BE, Schreiber S, Danese S, Kierkus J, Abhyankar B, Choi MY, Soo C, Wu Y, Sun F, Lee D, Cui D, Mangada M, Singhal P, Hussain A, Rogers BN, Peyrin-Biroulet L, Feagan BG. A Phase 2 Study of MORF-057, an Oral alpha4beta7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis. Clin Gastroenterol Hepatol. 2026 Feb;24(2):525-534. doi: 10.1016/j.cgh.2025.07.030. Epub 2025 Aug 6. PubMed 40769468 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Oct 2023, 18 months.

Results were first posted in Nov 2024, 1 year 1 month after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 18 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 23, 2022
StartActual
Apr 13, 2022
Primary completionActual
Oct 18, 2023
CompletionActual
Feb 19, 2025
Results first posted
Nov 26, 2024
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05291689
Responsible party
Sponsor
First posted
Mar 23, 2022
Start date
Apr 13, 2022
Primary completion
Oct 18, 2023
Completion
Feb 19, 2025
Results posted
Nov 26, 2024
Last update
Mar 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MORF-057

Start the discussion